Pharma Pixelbay Courtesy: Pixabay
21 October 2015

Will the TPP impact Indian pharma?

Do the TPP and the proposed India-EU trade deal extend protection of IPR, delaying generic competition for life-saving drugs and keeping their prices high? While these and other possible implications for Indian consumers and pharma companies become clearer over time, India must robustly engage with the debate on trade deals and public interest

Indian_Space_Research_Organisation_Logo.svg Courtesy: Wikipedia
23 September 2015

Space R&D: a strategic frontier

Instead of inviting foreign corporations to India to create a manufacturing base, Modi can use his Silicon Valley experience to build a similar research and development foundation in India for indigenous high-tech companies. A strategic space megaproject could be the start of this much-needed push.

Tech startups Courtesy: John Fischer/Flickr
6 August 2015

An agenda for Modi in Silicon Valley

Prime Minister Narendra Modi's outreach to the influential Indian diaspora in Silicon Valley in September should be centered on creating an Indian ecosystem for tech start-ups

Uber China Courtesy: Review Journal, Xinhua
30 April 2015

Can Uber in China counter local e-taxis?

Although Uber has a $41billion global valuation, over 99% of the taxi app market in China is controlled by local competitors offering personalised services, informal networks, and a familiarity with regulations that Uber cannot match. In such a scenario, can Uber live up to its valuation? And will local entities eventually also have an advantage in the crowd-sourced trucking and waterways sectors?

Hannover messe Courtesy: Hannover Messe.de
9 April 2015

Make German Mittelstand in India

Germany’s Mittelstand or medium and small companies are the heart beat of Germany’s successful economy. They will be showcased at the Hannover Fair, which Prime Minister Modi will inaugurate on April 12. It can be the perfect blueprint for his Make in India effort.

Gilead drugs Courtesy: media.licdn.com
19 February 2015

Examining the Gilead deal

Widely heralded as a success that brought together U.S. and Indian pharma producers over a high-cost drug at affordable prices, the Gilead deal looked ideal. A closer examination shows there’s more to consider than just low costs before the deal can become a template